AI Buyer Insights:

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Michelin, an e2open customer evaluated Oracle Transportation Management

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Michelin, an e2open customer evaluated Oracle Transportation Management

Aesica Pharmaceuticals Tech Stack and Enterprise Applications

Aesica Pharmaceuticals Collaboration
Vendor
Previous System
Application
Category
Market
VAR/SI
When
Live
Insight
Microsoft Legacy Microsoft 365 Collaboration Collaboration n/a 2019 2019
In 2019, Aesica Pharmaceuticals deployed Microsoft 365 as its Collaboration platform. Public references on the company's website indicate Microsoft 365 is used on their website, confirming organization-level adoption. The implementation leverages standard Collaboration capabilities such as Exchange Online mail, SharePoint Online content collaboration, Microsoft Teams messaging and meetings, and Office productivity applications. The deployment is structured as a cloud tenant with centralized administration and organization-wide provisioning, applying identity and access controls across corporate, quality, manufacturing, and R&D functions. Governance for a life sciences environment of this scale emphasizes information governance, retention policies, and role-based access controls implemented through Microsoft 365 configuration. Microsoft 365 supports document management, internal communications, and cross-functional collaboration across Aesica Pharmaceuticals.
Aesica Pharmaceuticals Content Management
Vendor
Previous System
Application
Category
Market
VAR/SI
When
Live
Insight
Exclaimer Legacy Exclaimer Cloud Signatures for Office 365 Digital Signing Content Management n/a 2019 2019
In 2019, Aesica Pharmaceuticals deployed Exclaimer Cloud Signatures for Office 365 to centralize corporate email signature management. The deployment is categorized as Digital Signing and is observable via Aesica's public site markup indicating Exclaimer usage. The implementation of Exclaimer Cloud Signatures for Office 365 was configured to provide centralized template and policy management, server side signature injection for Office 365 mail flow, and dynamic personalization using Office 365 directory attributes. Functional capabilities implemented include template versioning, role based administration for signature control, and policy rules to apply different signatures by department or user attribute. Integration scope centers on Office 365, with signature application tied into the organization's mail routing and directory data. Operational coverage focused on corporate email communications and branding, affecting marketing, corporate communications, and IT operations responsible for policy enforcement and signature lifecycle. Governance was organized around centralized administration and template approval workflows, enabling consistent branding and controlled updates to signature assets. The narrative reflects an application level implementation of Exclaimer Cloud Signatures for Office 365 within Aesica Pharmaceuticals, aligned to the Digital Signing category and integrated into Office 365 mail and directory services.

IT Decision Makers and Key Stakeholders at Aesica Pharmaceuticals

First Name Last Name Title Function Department Email Phone
No data found

Apps Being Evaluated by Aesica Pharmaceuticals Executives

APPS RUN THE WORLD tracks software evaluation trends across 2 million companies worldwide, including buyer insights from Aesica Pharmaceuticals IT executives and key decision makers. As part of ARTW Buyer Intent and technographics insights, these findings provide useful visibility into the Aesica Pharmaceuticals digital transformation priorities and AI adoption trends.
Date Company Status Vendor Product Category Market
No data found
FAQ - APPS RUN THE WORLD Aesica Pharmaceuticals Technographics
Aesica Pharmaceuticals is a Life Sciences organization based in United Kingdom, with around 212 employees and annual revenues of $36.1 million.
Aesica Pharmaceuticals operates a diverse technology stack with applications such as Microsoft 365 and Exclaimer Cloud Signatures for Office 365, covering areas like Collaboration and Digital Signing.
Aesica Pharmaceuticals has invested in cloud applications and AI-driven platforms to optimize efficiency and growth, collaborating with vendors such as Microsoft and Exclaimer.
Aesica Pharmaceuticals recently adopted applications including Microsoft 365 in 2019 and Exclaimer Cloud Signatures for Office 365 in 2019, highlighting its ongoing modernization strategy.
APPS RUN THE WORLD maintains an up-to-date database of Aesica Pharmaceuticals’s key decision makers and IT executives, available to Premium subscribers.
Our research team continuously updates Aesica Pharmaceuticals’s profile with verified software purchases, vendor relationships, and digital initiatives identified from public and proprietary sources.
Subscribe to APPS RUN THE WORLD to access the complete Aesica Pharmaceuticals technographics profile, including detailed breakdowns by category, vendor, and IT decision makers.